AIMS: To compare insulin sensitivity (Si) in adults at risk for type 2 diabetes (T2DM) who were categorized as non-depressed, treated for depression and untreated depression after controlling for physical activity (PA). METHODS: Baseline data was analyzed from individuals enrolled in a diabetes prevention program (n=56). Si was calculated using the whole-body insulin sensitivity method. The Centers for Epidemiologic Studies Depression Scale (CESD) was used to assess depressive symptoms and depressed cases were identified using a cutoff of >or=16. Depression treatment was identified using a self-report form validated by medical chart review. The PA subscale of the Health Promoting Lifestyle Profile was used to determine PA levels. RESULTS: One third of participants had elevated depressive symptoms; 19% were taking antidepressant medication. Mean Si was 3.1 (+/-1.9). In ANOVA, depressed individuals showed significantly lower Si (M=1.8+/-0.9) than non-depressed individuals (M=3.4+/-1.8). However, individuals taking antidepressant medications had Si similar to non-depressed individuals (M=3.7+/-2.3: p=.63). In ANCOVA this association remained after controlling for PA. CONCLUSIONS: These data suggest that in adults at high risk for T2DM, depression treatment may improve insulin resistance observed in depression. Healthcare practitioners are encouraged to screen, treat, or refer their patients with depression for treatment.
AIMS: To compare insulin sensitivity (Si) in adults at risk for type 2 diabetes (T2DM) who were categorized as non-depressed, treated for depression and untreated depression after controlling for physical activity (PA). METHODS: Baseline data was analyzed from individuals enrolled in a diabetes prevention program (n=56). Si was calculated using the whole-body insulin sensitivity method. The Centers for Epidemiologic Studies Depression Scale (CESD) was used to assess depressive symptoms and depressed cases were identified using a cutoff of >or=16. Depression treatment was identified using a self-report form validated by medical chart review. The PA subscale of the Health Promoting Lifestyle Profile was used to determine PA levels. RESULTS: One third of participants had elevated depressive symptoms; 19% were taking antidepressant medication. Mean Si was 3.1 (+/-1.9). In ANOVA, depressed individuals showed significantly lower Si (M=1.8+/-0.9) than non-depressed individuals (M=3.4+/-1.8). However, individuals taking antidepressant medications had Si similar to non-depressed individuals (M=3.7+/-2.3: p=.63). In ANCOVA this association remained after controlling for PA. CONCLUSIONS: These data suggest that in adults at high risk for T2DM, depression treatment may improve insulin resistance observed in depression. Healthcare practitioners are encouraged to screen, treat, or refer their patients with depression for treatment.
Authors: Debbie A Lawlor; Yoav Ben-Shlomo; Shah Ebrahim; George Davey Smith; Stephen A Stansfeld; John W G Yarnell; John E J Gallacher Journal: BMJ Date: 2005-01-31
Authors: Maria Gilles; Annette Wilke; Daniel Kopf; Annemarie Nonell; Hendrik Lehnert; Michael Deuschle Journal: Psychosom Med Date: 2005 Sep-Oct Impact factor: 4.312
Authors: Robert P Kauffman; V Daniel Castracane; Debie L White; Sandra D Baldock; Ron Owens Journal: Gynecol Endocrinol Date: 2005-09 Impact factor: 2.260
Authors: Patrick J Lustman; Ray E Clouse; Billy D Nix; Kenneth E Freedland; Eugene H Rubin; Janet B McGill; Monique M Williams; Alan J Gelenberg; Paul S Ciechanowski; Irl B Hirsch Journal: Arch Gen Psychiatry Date: 2006-05
Authors: Anne Herva; Pirkko Räsänen; Jouko Miettunen; Markku Timonen; Kristian Läksy; Juha Veijola; Jaana Laitinen; Aimo Ruokonen; Matti Joukamaa Journal: Psychosom Med Date: 2006 Mar-Apr Impact factor: 4.312
Authors: Melissa Hanahan Madden; Philip Tomsik; Joshua Terchek; Lisa Navracruz; Ann Reichsman; Terri Clemons Clark; Peggi Cella; Stephen A Weirich; Michelle R Munson; James J Werner Journal: J Natl Med Assoc Date: 2011-03 Impact factor: 1.798
Authors: O Birnbaum-Weitzman; R Goldberg; B E Hurwitz; M M Llabre; M D Gellman; M Gutt; J R McCalla; A J Mendez; N Schneiderman Journal: Diabet Med Date: 2013-12-18 Impact factor: 4.359
Authors: Itamar Levinger; Steve Selig; George Jerums; Andrew Stewart; Cadeyrn J Gaskin; David L Hare Journal: Diabetol Metab Syndr Date: 2012-11-21 Impact factor: 3.320